Literature

From Pages to Practice

By Krista Nottage, MBBS

Published August 28, 2019

res360

Paul is a 51-year-old man who was recently diagnosed with nephrotic syndrome due to primary membranous nephropathy. Despite good blood pressure management and a low-protein, low-salt diet, Paul’s recent work up shows persistent proteinuria of 6 g/day and worsening creatinine levels (from 1.1 to 1.5 mL/min/1.73m2).  What are the options for the next step in his care?

Current management strategies in patients with persistent nephrotic syndrome have relied on immunosuppressive therapy with a regimen of alternating glucocorticoids and cyclophosphamide or a calcineurin inhibitor (e.g., cyclosporine). The anti-CD20 monoclonal antibody rituximab has shown promise in the treatment of membranous nephropathy owing to the selective depletion of B-cell dysfunction that appears to be central to the pathogenesis of this condition.

In the open-label, randomized, noninferiority Membranous Nephropathy Trial of Rituximab (MENTOR) published in the NEJM, rituximab was found to be superior to cyclosporine — the current preferred therapy — in inducing and maintaining remission of proteinuria. At 24 months, 60% of patients treated with rituximab had partial or complete remission of proteinuria versus only 20% of patients treated with cyclosporine. The importance of these findings is that rituximab has been associated with better preservation of kidney function and a lower incidence of relapse, compared with cyclosporine.

The following NEJM Journal Watch summary explains the study and results in further detail:

res360

Rituximab for Membranous Nephropathy

Allan S. Brett, MD reviewing Fervenza FC et al. N Engl J Med 2019 Jul 4 Ruggenenti P and Remuzzi G. N Engl J Med2019 Jul 4

Membranous nephropathy is a common cause of nephrotic syndrome in adults. Many patients can be observed without initiating immunosuppressive treatment; however, patients at substantial risk for progressive disease (according to serial measurements of urine protein and glomerular filtration rate) typically are treated with cyclophosphamide plus glucocorticoid or with a calcineurin inhibitor (e.g., cyclosporine). In this industry-funded randomized trial, 130 adults with membranous nephropathy who were at moderate-to-high risk for progression received either cyclosporine or the anti-CD20 monoclonal antibody rituximab. At enrollment, median urinary protein was 8.9 g per 24 hours, median serum creatinine was 1.3 mg/dL, and median serum albumin was 2.5 g/dL.

At 24 months, the incidence of complete remission (≤0.3 g proteinuria/24 hours) or partial remission (≥50% reduction in proteinuria, to a level between 0.3 and 3.5 g/24 hours) was significantly higher with rituximab than with cyclosporine (60% vs. 20%). The incidence of serious adverse events was somewhat higher with cyclosporine than with rituximab (31% and 17%; P=0.06).

Comment: Currently, rituximab generally is reserved for patients with membranous nephropathy whose disease has been resistant to standard therapies. These results suggest that rituximab might become a first-line treatment option in selected patients.

Browse more From Pages to Practice »

res360
Krista is a 2019-2020 editorial fellow at the New England Journal of Medicine. She is from Nassau, Bahamas where she is training in general surgery at the University of the West Indies.
NEJM Knowledge+